{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=19",
    "query": {
      "intervention": "Estring",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 887,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T16:35:33.120Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02080468",
      "title": "Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "lomitapide",
          "type": "DRUG"
        },
        {
          "name": "EE/norgestimate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2014-02-19",
      "completion_date": "2014-04-24",
      "has_results": true,
      "last_update_posted_date": "2019-03-11",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02080468"
    },
    {
      "nct_id": "NCT01186796",
      "title": "Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 80 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2009-06",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2015-03-27",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186796"
    },
    {
      "nct_id": "NCT00821496",
      "title": "Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ethinyl estradiol, norethindrone, VI-0521",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 64 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2009-01",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2009-12-02",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821496"
    },
    {
      "nct_id": "NCT04901299",
      "title": "Fulvestrant + Neratinib In Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV (Metastatic) Breast Cancer",
        "Metastatic Breast Cancer",
        "ER Positive Breast Cancer",
        "PR-Positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Invasive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NERATINIB",
          "type": "DRUG"
        },
        {
          "name": "FULVESTRANT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-07",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04901299"
    },
    {
      "nct_id": "NCT03240081",
      "title": "Treating Postmenopausal Dyspareunia Where it Hurts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dyspareunia"
      ],
      "interventions": [
        {
          "name": "50mcg estradiol cream",
          "type": "DRUG"
        },
        {
          "name": "100mcg estradiol cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2017-06-20",
      "completion_date": "2019-11-21",
      "has_results": true,
      "last_update_posted_date": "2023-05-22",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03240081"
    },
    {
      "nct_id": "NCT00179426",
      "title": "Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Seizure Disorder",
        "Epilepsy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 175,
      "start_date": "1999-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179426"
    },
    {
      "nct_id": "NCT00399685",
      "title": "Drug Interaction - Oral Contraceptive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ortho Tri-Cyclen LO",
          "type": "DRUG"
        },
        {
          "name": "Ortho Cyclen",
          "type": "DRUG"
        },
        {
          "name": "Ortho Cyclen + Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2006-12",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Tacoma, Washington",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00399685"
    },
    {
      "nct_id": "NCT05524584",
      "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-08-31",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05524584"
    },
    {
      "nct_id": "NCT06026553",
      "title": "Assessing Ketorolac (Toradol) at Oocyte Retrieval",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infertility",
        "Infertility, Female",
        "Oocyte Retrieval",
        "Postoperative Pain",
        "Embryo Transfer"
      ],
      "interventions": [
        {
          "name": "Ketorolac (Toradol)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shady Grove Fertility Reproductive Science Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 400,
      "start_date": "2022-08-10",
      "completion_date": "2025-01",
      "has_results": false,
      "last_update_posted_date": "2023-09-07",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 2,
      "location_summary": "Rockville, Maryland • Fairfax, Virginia",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026553"
    },
    {
      "nct_id": "NCT00808132",
      "title": "Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "bazedoxifene 20 mg/ conjugated estrogens 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "bazedoxifene 20 mg/ conjugated estrogens 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "bazedoxifene 20 mg",
          "type": "DRUG"
        },
        {
          "name": "conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 64 Years · Female only"
      },
      "enrollment_count": 1886,
      "start_date": "2009-01",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-10-23T16:35:33.120Z",
      "location_count": 143,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00808132"
    }
  ]
}